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Background: The incidence of chronic obstructive pulmonary disease (COPD) in China is very high. This study
aimed to assess the vulnerability of COPD patients in rural areas outside Xuzhou City, Jiangsu province, in order to
provide helpful guidance for future research and public policies.
Methods: The vulnerability of 8,217 COPD patients was evaluated using a face-to-face questionnaire to obtain
information on general characteristics, awareness, beliefs, medication usage, acute exacerbation of the disease, and
economic burdens. Direct economic burdens were calculated based on the questionnaire, and indirect economic
burdens were estimated using local per capita income and life expectancy in 2008. The years of potential life lost
were calculated using loss of life years for each age group and multiplying by the number of deaths in a given age
group.
Results: Of the 8,217 patients, 7,921 (96.4%) had not heard of COPD, and 2,638 (32.1%) did not understand that
smoking was a risk factor for COPD. No patients had used inhalers, nebulizer drugs or oxygen therapy, either
regularly or sporadically. No patients had undergone pulmonary rehabilitation or surgical treatment, while 4,215
(51.3%) took theophylline to relieve dyspnea, and 3,418 (41.6%) used antibiotics to treat exacerbations. A total of
2,925 (35.6%) patients had been admitted to hospital during the past year because of respiratory symptoms. The
average direct and indirect economic burdens on COPD patients were 1,090 and 20,605 yuan, respectively.
Conclusions: The vulnerability of patients in rural Xuzhou to COPD was high. Their awareness of COPD was poor,
their treatment during both the stable and acute exacerbation stages did not meet standards, and the economic
burdens were large. Interventions are therefore needed to improve the prevention and management of COPD in
this population. Further studies are required to verify these findings.
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Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease [1,2], but it remains a sig-
nificant public health problem. It is a major chronic
cause of mortality and morbidity and has been identified
as the third leading cause of mortality and morbidity
worldwide [3-5]. The World Health Organization
(WHO) estimated that 274 million people worldwide* Correspondence: loupeian2004@yahoo.com.cn
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reproduction in any medium, provided the ordied of COPD in 2000 [1]. An estimated 43 million men
and women in China have COPD [6], and the disease
mortality is about 1.6% [7]. Management of patients with
COPD must therefore become a priority in China.
COPD is characterized by airflow limitation that is not
fully reversible, and a progressive decline in lung function
[1]. Patients often exhibit chronic dyspnea and bronchitis,
coughing, sputum production, and pathologic features of
emphysema. COPD is often accompanied by exacerbation
of respiratory symptoms requiring hospitalization [8]. The
goals of managing stable COPD include reducing the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ling baseline symptoms [1,9,10].
The management of patients with COPD depends
upon their understanding and recognition of the disease
[11-13]; they then need to seek out a general practitioner
who must also recognize the condition [14]. However,
current management of COPD is primarily based on
hospitalized cases in urban districts [15,16], and little at-
tention has been paid to community-based cases in
other areas.
Vulnerability refers to the susceptibility of a popula-
tion to risks, reflected in the likelihood and extent of
population health losses caused by certain factors or
changes to the health-care system [17]. Vulnerability can
influence people’s competence, increase their susceptibil-
ity to disease, and prolong recovery [18]. The cognitive
vulnerability of COPD patients is affected by personal
factors, social environment, medical history, and many
other factors. Personal factors include a lack of know-
ledge of methods for the prevention and control of
COPD, poor lifestyle, attitude, and high-risk behaviors.
The social environment includes social support, avail-
ability of information, health care, economic aspects,
and other factors. To evaluate the vulnerability of a
population, it is necessary to identify the factors that
lead to these aspects of vulnerability. Studies of the ex-
tent of cognitive vulnerability in patients with COPD
can provide a scientific basis for developing targeted
control measures.
This study therefore aimed to evaluate the vulnerabil-
ity of patients with COPD, with respect to their compre-
hension of the disease, treatments and economic
burdens, and to provide scientific evidence to improve




Tongshan County, in the Xuzhou City region of Jiangsu
province, has 28 townships and 1.14 million inhabitants.
From a total of 1.10 million health records screened by
the end of 2007, 24,641 cases of COPD were uncovered
according to the COPD diagnosis and treatment guide-
lines criteria (revised 2007) [19]. The patients enrolled in
the study are listed in Figure 1. According to the Global
Initiative for Chronic Obstructive Lung Diseases
(GOLD), COPD can be divided into levels I–IV [20].
Questionnaire design
We designed a vulnerability questionnaire based on
previously published domestic and foreign literature
[21-23], which included information on aspects in-
cluding epidemiology, prevention, treatment, and re-
habilitation. The survey instrument consisted of 75items and was divided into five domains: demographic
data (10 items), cognition of COPD (15 items),
behaviors (5 items), disease management (10 items),
qualities of life (25 items) and economic burdens
(10 items).
Measurements of general data
The 8,217 patients with COPD were interviewed face-
to-face in their homes. Information on age, gender,
current employment status, level of education, cigarette-
smoking status, marital status, physical activity, family
history of COPD and other conditions were obtained
using the designed questionnaire. The interview also
obtained data on the cost of hospitalizations, outpatient
costs, outpatient accommodation, in-home treatment
costs, and the costs of long-term medication regimens
including drugs purchased at the patient’s own expense,
self-medication drugs, and costs related to lost product-
ivity and lost employment in the last year (by examining
the patient’s hospital records and records from township
and village clinics). Hospital accommodation costs
included the costs of patient transportation and meals,
their escorts, and employment costs paid to caregivers.
Calculation of economic burdens
Direct economic burdens were calculated using the
questionnaire. Indirect economic burdens were esti-
mated using local per capita income and life expectancy
for 2008. In order to estimate the risk of premature
death, the number of years of potential life lost (YPLL)
as a result of COPD per 100,000 people was assessed.
According to the local life expectancy statistics, the
reference survival age was set at 70 years, and the loss of
potential life was defined as between 70 years and the
age of the patient at death. The age composition of Chi-
na's population census report of 2000 was used to adjust
the composition of the population in 2008 in Tongshan
County. The YPLL was calculated as follows: YPLL=Σ
(ai × di), where ai = loss of life years for a certain age
group, and di = the number of deaths in a given age
group. Average YPLL=YPLL/deaths [24].
This study was carried out between March 2008 and
March 2009 in the rural area surrounding Xuzhou City
in Jiangsu province, China. The study was approved by
the Ethics Committee of the Xuzhou Center for Disease
Control and Prevention, and the Regional Ethical
Vetting Board, Xuzhou, China. Informed consent (verbal
and written in English, translated to Igbo when neces-
sary) was obtained from all participants.
Statistical analysis
Data analysis was performed using the Statistical Package
for Social Science (SPSS) version 13.0. Numerical variables
were expressed as means± standard deviations (SD). For
12,875 patients out of 0.6 million 
inhabitants in 14 towns 
Exclusion criteria: severe heart, liver, 




24,641 patients out of 1.14 million 
inhabitants in 28 towns 
Total patients screened 
(n=8938) 
Declined to take part 




Respondents who then competed  
only the partial survey 
(n=85) 
Respondents who were  
eligible for the survey 
(n=8217) 
Respondents who didn’t compete 
 the economic survey 
(n=834) 
Respondents who were eligible  
for the economic analyze 
(n=7383) 
Died (n=201) 
Figure 1 Sample construction.
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A total of 8,302 questionnaires were sent out and all were
returned. Of these, 8,217 were complete and valid, giving a
response rate/compliance rate of 99.0%. There were 3,930
male patients and 4,287 female patients (Table 1). Patient
ages ranged from 36–84 years (mean±SD, 61.3±14.3).
Patients between 55 and 75 years of age accounted for
63.4% of the total. According to the GOLD classification
criteria, 1,216 patients with COPD were classified as stage I
(14.8%), 3,435 as stageII(41.8%), 2,161 as stage III (26.3%),
and 1,405 as stage IV (17.1%).
Cognitive vulnerability
Among all the patients, 7,921 (96.4%) had never heard
the term ‘COPD’, and most of them thought they hadcontracted chronic bronchitis or bronchial asthma. The
cognitive vulnerabilities are shown in Table 2. Although
most patients were concerned about their health, 6,163
(75.0%), had taken no appropriate measures, such as
preventing cold, maintaining a regular vaccination
schedule or taking globulin injections. However, 93.9%
of patients said that they were willing to change their
behaviors (including quitting smoking and undergoing
rehabilitation or physical training) to delay development
of the disease. Only a very small number of patients had
no opinion or were unwilling to change their unhealthy
behaviors.
Vulnerability to disease management
The local health administration had not implemented
any health-education programs for COPD patients, such
as quitting smoking and maintaining a reasonable diet.
Of the total, 649 (7.9%) patients did not wish to accept
treatment because they thought their condition was
















live alone 1,018 12.4
live with spouse 4,547 55.3




primary school 1739 21.2
junior school 1,090 13.3
high school 723 8.8











Table 2 Cognitive vulnerability of patients with COPD
Variable N (%)
Never heard the term ‘COPD’ 7,921 96.4
Told they had the following diseases, rather
than COPD
chronic bronchitis 6,541 79.6
emphysema 1,241 15.1
bronchial asthma 444 5.4




passive smoking 3,106 37.8
air pollution 3,878 47.2
exposure to cold air and change in climate 7,691 93.6
Believed their conditions were due to after effects of
the following diseases
chronic bronchitis 3,920 47.7
asthma 3,500 42.6
not knowing smoking was the main risk factor 2,638 32.1
had taken no appropriate measures 6,163 75.0
willing to change their bad behaviors 7,716 93.9
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treatment but were unable to continue to do so for
financial reasons. None of the patients had used inhalers,
nebulizer drugs or oxygen therapy, either regularly or
sporadically. None of the patients had undergone pul-
monary rehabilitation or surgical treatment, while 4,215
(51.3%) patients took theophylline to relieve their dys-
pnea, and 3,418 (41.6%) used antibiotics to treat exacer-
bation. Most patients underwent treatment in the village
or township hospitals, but this treatment was informal
and spontaneous. A total of 2,925 (35.6%) patients had
received in-patient treatment in township hospitals due
to respiratory symptoms within the past year.Economic vulnerability
The mean monthly per capita income of patients with
COPD was (300 ± 165) yuan, while that of 3,541 (43.1%)
patients was below 300 yuan. The yearly net per capita
income of a farmer in Tongshan County was 6,340 yuan
in 2008, or 528 yuan per month. The monthly per capita
income of patients with COPD was 34.1% lower than
that of the general population. COPD patients were un-
able to work for a mean of 150 days per year, while fam-
ily members were prevented from working for a mean of
59 days per year. The median direct economic burden of
patients with COPD in the rural areas in Tongshan
County was 1,090 yuan; the medical costs of the 7,383
patients were 14,042,466 yuan, and the per capita
economic burden was 1,902 yuan. The cost of outpatient
services was 5,939,963 yuan, accounting for 42.3% of the
total. This was followed by hospitalization costs
(4,563,801 yuan, 32.5%) and long-term self-financed
medicines (2,878,710 yuan, 20.5%). These three categor-
ies accounted for 95.3% of COPD-related medical costs.
The mean yearly per capita income of families of COPD
patients was 3,600 yuan, and the mean yearly direct eco-
nomic burden of one COPD patient was 1,090 yuan.
COPD therefore accounted for an average of one third
of the family income. Regarding the indirect economic
burden, the total YPLL of patients living in Tongshan
County in 2008 was 682.5 years, with an average of
3.25 years per patient, calculated using the formula,
YPLL =Σ (ai × di). The total number of years lost by men
was 427.5, with an average of 1.76 per person. The
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average of 1.18 per person. Taking into account Tong-
shan farmers’ yearly net per capita income (6,340 yuan)
in 2008, the indirect economic loss caused by COPD
was estimated at 4,327,050 yuan in total, and 20,605
yuan per capita.
Discussion
This is the first study to investigate the vulnerabilities
caused by COPD in China. The results indicated high
cognitive vulnerability of COPD patients in rural areas
of Xuzhou. Although health education is the most effect-
ive means of improving symptoms in patients with
COPD [25], no health education programs were imple-
mented in the current survey region. Most of the
patients (96.4%) in the current study had never heard
the term ‘COPD’ before, which was fewer than reported
by Walker et al. [26]. Lung function tests and health
education programs were not implemented in these
patients either. These results were also consistent with
the findings published by Ning et al. [27]. Tobacco
smoking is the best-known causal factor associated with
the development of COPD, and cessation of smoking is
the only measure that can prevent the disease and mod-
ify its clinical course [28]; however, our results showed
that 32.1% of patients did not know that smoking was
the main risk factor for COPD. The health education
system thus needs to be improved in order to raise the
awareness of patients to COPD.
Medication can effectively prevent and control the
symptoms of COPD, reduce the frequency and severity
of exacerbations, and improve both exercise tolerance
and quality of life [29,30]. Optimizing management of
COPD patients, especially stable patients, can reduce the
frequency of acute episodes [31]. Our survey showed
that patients in rural Xuzhou were highly vulnerable to
poor disease management. None of the stable patients
received regular drug treatment, and the drug-regimen-
compliance rate was significantly lower than that
reported by Barr et al. [32]. No individuals used inhalers
or spray treatments during the acute exacerbation stage
of COPD, which is well below the normal rate of inhaler
use of approximately 10%, reported by Restrepo et al.
[33]. There has been a recent increase in interest in pul-
monary rehabilitation programs, in line with clinical evi-
dence clearly demonstrating reduced dyspnea, increased
exercise tolerance, improved physical and emotional par-
ticipation, and decreased health-care costs [34]. The
current results showed that none of the patients in rural
Xuzhou understood how to perform rehabilitation exer-
cises. Influenza vaccination has been shown to prevent
acute respiratory infections in patients with all severities
of COPD [35], and influenza and pneumococcal vaccina-
tions are recommended as an important risk-reductionstrategy [36]. Additionally, mainly for financial reasons,
patients in the current study were only hospitalized in
rural hospitals, which did not provide health education.
The yearly per capita net income of Tongshan rural
farmers in 2008 was 6,340 yuan, or 528 yuan per month,
but the monthly per capita net income of COPD
patients was 34.1% lower. The average annual income of
COPD patients’ families was 3,600 yuan, which was
43.2% lower than that of rural farmers. In addition,
COPD patients experienced an annual direct economic
burden of 1,090 yuan as a result of medical expenses,
accounting for one third of their families’ incomes.
COPD caused a potential loss of 3.25 years of life per pa-
tient, which was higher than that reported by Fei et al.
[36]. The indirect loss of income was calculated to be as
high as 20,605 yuan per capita, indicating that COPD
had a detrimental effect on the local population. In
addition to more measurable losses, many patients lost
their ability to work. This direct economic burden was
less than that reported for developed countries, such as
Spain, the United States and many European countries
[37,38]. However, the annual per-capita income in these
countries is also much higher than in rural China, and
the COPD patients in this study might thus suffer a lar-
ger direct economic burden than patients in the U.S.
and Europe.
This study was limited by focusing primarily on farm-
ers, who do not have fixed working hours. This made it
difficult to calculate accurately the number of working
days lost as a result of disease. Patients also lacked for-
mal treatment, and it was therefore difficult to obtain re-
liable information on medical economics.Conclusions
Patients with COPD experienced greater cognitive vulner-
ability, poorer disease management, and greater disease
burden than healthy people. Interventions are needed to
improve the prevention and management of COPD. Fur-
ther studies are needed to verify these findings.
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